If the troublesome symptoms are still present after the medical, psychiatric and psychosocial causes of the mental status changes have been either ruled out or treated, then a trial of behavioral modification and/or medication can be offered for symptomatic relief and management. In compliance with the Nursing Home Reform Amendments of the 1987 Omnibus Budget Reconciliation Act (OBRA), professionals often seek to reduce the inappropriate use of psychotropic medications among nursing home patients (Sunderland, 1995) . However, pharmacological treatment (See Table) is needed if behavioral agitation places the patient or others in danger or interferes significantly with either the individual's care or the care of other patients (American Psychiatric Association, 1997; Jung and Grossberg, 1993) . The U.S. Food and Drug Administration has not approved any medication for the treatment of behavioral agitation in dementia. However, the first line of defense is usually a traditional major tranquilizer such as haloperidol (Haldol), thioridazine (Mellaril), thiothixene (Navane) or perphenazine (Etrafon, Trilafon). These agents do not always produce good results and are most useful if the agitation is associated with psychotic features (Alexopoulos et al., 1998 [Alexopoulos et al., 1998 ]-Ed.)
The newer atypical antipsychotic agents, such as risperidone (Risperdal), clozapine (Clozaril), olanzapine (Zyprexa) and quetiapine (Seroquel) offer the promise of treatment with an improved side-effect profile (Raskind, 1998; Kumar, 1997) .
The benzodiazepines with shorter half-lives, such as lorazepam (Ativan), oxazepam (Serax) and alprazolam (Xanax) can be useful, particularly if anxiety and tension are a major component of the agitation. The benzodiazepines stay in the body a short period of time, and can be ordered on an as-needed basis. Side effects include sedation, amnesia, confusion and a paradoxical response. They can intensify cognitive slowing, cause dependence and produce changes in equilibrium that can contribute to increased risk of falls and fractures. Long-term use can lead to habituation and dependence.
Withdrawal symptoms can occur, particularly if the patient goes into the hospital or nursing home, and doesn't reveal all of the medications that he or she has been taking. Buspirone (BuSpar), a serotonergic azapirone anxiolytic, also has been used for agitation (Cantillon et al., 1996) . It is an alternative to the benzodiazepines and does not produce their undesirable side effects. It has a slower onset of action, but shows little or no sedation and few drug-drug or drug-alcohol interactions. It does not impair psychomotor performance. Unlike benzodiazepines, it is not associated with withdrawal reactions and lacks dependence/abuse potential as evidenced by studies of drug discrimination and withdrawal in animals and clinical experience with patients, especially known substance abusers (Ayd, 1995 The serotonergic antidepressant trazodone (Desyrel) has been used to treat agitation (Houlihan et al., 1994) . Its principal side effects include postural hypotension, sedation and dry mouth (American Psychiatric Association, 1997).
SSRIs, such as sertraline (Zoloft), paroxetine (Paxil), fluvoxamine (Luvox), fluoxetine (Prozac) and citalopram (Celexa) are useful if symptoms of depression, anxiety or irritability are prominent (Alexopoulos et al., 1998; Nyth and Gottfries, 1990) . In a multicenter Scandinavian study (Nyth and Gottfries, 1990) , citalopram was more effective than placebo for the target symptoms of irritability, fear and panic, depressed mood, and restlessness. Improvement was limited to patients with Alzheimer's disease. No significant effects of citalopram were noted in patients with vascular dementia. (The SSRIs, themselves, however, may occasionally be associated with akathisia-like reactions [Perry et al., 1997]-Ed.) Other medications that have been tried for chronic agitation include beta-blockers such as propranolol (Inderal) and pindolol (Visken) (Weiler et al., 1988) 
Agitation in the Elderly
Published on Psychiatric Times (http://www.psychiatrictimes.com) Depo-Provera) and related hormonal agents have been used for the treatment of intrusive disinhibited sexual behavior (American Psychiatric Association, 1997). The anticonvulsants, such as carbamazepine (Epitol, Tegretol) and valproate (Depakene, Depakote), appear to show promise in the management of the behavioral complications of dementia. They may work by facilitating a brain chemical, GABA, deficient in dementia. If the behavioral agitation in dementia represents a form of organic mania, anticonvulsants may be effective based on their mood-stabilizing properties. The effectiveness of carbamazepine has been variable, showing improvement of up to 50% in patients with agitation associated with mood lability, aggression or anxiety (Chambers et al., 1982; Gleason and Schneider, 1990; Lemke, 1995; Tariot et al., 1994) . Carbamazepine has potential for drug-drug interactions, effects on the white cell blood count and toxicity. Its principal side effects include unsteadiness, drowsiness, dizziness and confusion. Valproate may be as effective and a safer treatment for the behavioral complications of dementia, particularly of the Alzheimer's type. It is most helpful with symptoms of physical aggression. Valproate appears to be better tolerated due to a more benign side effect profile and fewer drug-drug interactions. It may reduce behavioral agitation without sedation or other cognitive or neurological side effects (Lott et al., 1995; McElroy et al., 1996) . Gastrointestinal distress, such as nausea, dyspepsia and diarrhea, and weight gain are possible but infrequent. These effects can be further minimized by the use of divalproex sodium, a delayed-release tablet. Published studies show no significant laboratory abnormalities. The rare occurrence of hepatic transaminase elevations and thrombocytopenia are both reversible (American Psychiatric Association, 1997; McElroy et al., 1996; Sanborn et al., 1995) .
The treatment of behavioral symptoms is complex and difficult. The preceding options may improve the quality of life, maximize functioning and diminish the need for custodial care in agitated demented patients. They can reduce suffering and stress, as well as increase the comfort and safety of patients and caregivers. Etiologies may be multifactorial requiring both nonpharma-cological and pharmacological interventions. A biopsychosocial approach is best. More work is still needed in this important clinical area.
However, even if these therapies are successful, the physician's job is not complete unless he or she also focuses on the caregivers. They need to be educated about the dementia, available treatments and sources of care and support; given empathetic help in making informed decisions symptoms of; and given hope. Their physical health and emotional resiliency are essential to the successful management of agitation in the elderly. 
